UNION therapeutics announces full-year results for 2022 and provides business update
Hellerup, Denmark, February 9, 2023, – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces full-year results for the period January 1 to December 31, 2022. 2022 has been a year of great progress for UNION with several important achievements paving the way for a very exciting 2023, including positive topline results from the Phase 2b study with oral orismilast in psoriasis, advancement of our mid- to late-stage clinical programs with orismilast and niclosamide,